New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
04:55 EDTACHC, ACHC, ACHC, BABY, BABY, BABY, CNC, CNC, CNC, INCY, INCY, INCY, AUXL, AUXL, AUXL, HGR, HGR, HGR, ALKS, ALKS, ALKS, ACHN, ACHN, ACHN, MZOR, MZOR, MZOR, LMNX, LMNX, LMNX, IDIX, IDIX, IDIXUBS to hold a conference
Global Healthcare Conference to be held in New York on May 19-21.
News For IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
07:33 EDTINCYBrean Capital to hold a summit
Subscribe for More Information
November 21, 2014
08:35 EDTAUXLBioSpecifics announces new data on XIAFLEX for Peyronie's Disease
Subscribe for More Information
08:01 EDTCNCCentene jv selected to provide correctional healthcare In Vermont
Subscribe for More Information
November 20, 2014
08:25 EDTINCYIncyte management to meet with UBS
Subscribe for More Information
07:09 EDTAUXLAuxilium presents STENDRA data at SMSNA meeting
Auxilium Pharmaceuticals announced that data were presented regarding the use of STENDRA tablets for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. A post-hoc analysis of data from a placebo-controlled, Phase 4 study of STENDRA evaluated men who had at least one attempt at intercourse within approximately 15 minutes of taking the medication. The STENDRA 100 and 200mg doses demonstrated statistically significant improvement in onset of erectogenic effect at approximately 15 minutes compared to placebo, with a mean per-patient proportion of sexual attempts that resulted in at least one successful intercourse within approximately 15 minutes after dosing of 73.3% and 71.5%, respectively. Results of a study examining the proportion of men with ED who reported successful intercourse within the first three doses of STENDRA showed more than 60% of patients reported successful intercourse within the first three doses of STENDRA. This compares to about 40% with placebo. A higher percentage, or 75% for STENDRA vs. 56% for placebo, also reported success after any dose.
07:07 EDTAUXLAuxilium presents XIAFLEX for Peyronie's Disease data
Auxilium Pharmaceuticals announced presentations of data from new studies, as well as new analyses of data from the Phase 2 and the pivotal Phase 3 IMPRESS trials evaluating XIAFLEX for the treatment of Peyronie's disease, at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. Data were presented providing further evidence that PD bother is clinically significant and may be a useful measure in clinical practice when treating PD. Data were also presented suggesting that improvements in PD bother are correlated with improvements in penile curvature deformity.
November 19, 2014
10:21 EDTCNCHigh option volume stocks
Subscribe for More Information
07:33 EDTAUXLEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
05:44 EDTACHNStocks with implied volatility movement; MCD KO
Subscribe for More Information
November 18, 2014
07:02 EDTAUXLAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information
November 17, 2014
11:06 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:16 EDTALKSMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
05:10 EDTHGRHanger postpones release of Q3 results
Hanger announced that it is postponing the release of its Q3 financial results and is cancelling its previously scheduled earnings conference call to allow additional time for the completion and review of its Q3 financial statements. The company will release its Q3 financial results and reschedule its conference call after the completion and review of its Q3 financial statements.
November 14, 2014
11:33 EDTHGRHanger management to meet with SunTrust
Meetings to be held in New York on November 18 and in the Mid-Atlantic area on November 19 hosted by SunTrust.
November 13, 2014
13:32 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
11:54 EDTALKSJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:01 EDTCNCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Hold from Buy at Argus... Adeptus Health (ADPT) downgraded to Hold from Buy at Deutsche Bank... American Woodmark (AMWD) downgraded to Neutral from Buy at Longbow... Avnet (AVT) downgraded to Sell from Neutral at Goldman... Baxano Surgical (BAXS) downgraded to Sell from Buy at Summer Street... Beazer Homes (BZH) downgraded to Neutral from Overweight at JPMorgan... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley... Centene (CNC) downgraded to Market Perform from Outperform at FBR Capital... Cherry Hill Mortgage (CHMI) downgraded to Equal Weight from Overweight at Barclays... Discover (DFS) downgraded to Hold from Buy at Deutsche Bank... Fleetmatics (FLTX) downgraded to Neutral from Buy at BofA/Merrill... Gazprom (OGZPY) downgraded to Neutral from Overweight at JPMorgan... Jabil Circuit (JBL) downgraded to Neutral from Buy at Goldman... LabCorp (LH) downgraded to Hold from Buy at Deutsche Bank... Laredo Petroleum (LPI) downgraded at BMO Capital... Macy's (M) downgraded to Market Perform from Outperform at Wells Fargo... Madison Square Garden (MSG) downgraded to Equal Weight from Overweight at Morgan Stanley... Marvell (MRVL) downgraded to Sell from Neutral at Goldman... Meritor (MTOR) downgraded to Neutral from Overweight at Piper Jaffray... Swedbank (SWDBY) downgraded to Underperform from Sector Perform at RBC Capital... TransGlobe (TGA) downgraded to Sector Perform from Outperform at Scotia Capital... UIL Holdings (UIL) downgraded to Hold from Buy at Argus... Verint Systems (VRNT) downgraded to Fair Value from Buy at CRT Capital... ZAIS Financial (ZFC) downgraded to Equal Weight from Overweight at Barclays.
06:29 EDTCNCCentene downgraded to Market Perform from Outperform at FBR Capital
FBR Capital downgraded Centene to Market Perform citing valuation following the recent rally in shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use